JP2018527364A - Composition for promoting differentiation of muscle cells containing amino acid - Google Patents

Abstract

The present invention relates to a composition for promoting differentiation of muscle cells containing an amino acid, more specifically, a composition for promoting differentiation of muscle cells comprising phenylalanine and methionine, a pharmaceutical composition for preventing or treating senile muscle loss containing the same, and The present invention relates to a health functional food composition for preventing or improving senile muscle loss. The composition for promoting the differentiation of muscle cells of the present invention and the pharmaceutical composition or health functional food composition containing the composition promotes the differentiation of myoblasts into muscle cells to prevent or improve muscle loss or muscle loss. In particular, it is effective for senile muscle loss, and has the effect of increasing the basal metabolic rate due to the increase in the number of muscle cells and oxidizing fatty acids in the body. [Selection] Figure 1

Description

  The present invention relates to a composition for promoting differentiation of muscle cells containing an amino acid, more specifically, a composition for promoting differentiation of muscle cells comprising phenylalanine and methionine, a pharmaceutical composition for preventing or treating senile muscle loss containing the same, and The present invention relates to a health functional food composition for preventing or improving senile muscle loss.

  The muscles of our body perform various functions such as attaching to the bones to protect the bones and to maintain the body shape correctly. Muscles also promote calcium influx and increase bone density. However, as the body ages, redistribution of body fat and body protein occurs due to changes in the components, and at about 50 years of age, the protein synthesis rate in muscle cells is slower than the degradation rate, causing muscles to degenerate rapidly. As you begin, you may be exposed to muscle loss.

  Muscle loss, one of the diseases of muscle loss, usually refers to a state in which about 13 to 24% of your body mass has been reduced, and if you have muscle loss, the amount of action will be greatly reduced and mental health will be impaired. In addition, the level of satisfaction with life is reduced, and even in simple daily life, it is easily injured, resulting in serious injuries.

  Causes of sarcopenia can be attributed to gradual decrease in the amount and quality of skeletal muscle that occurs as aging progresses and weight loss including fat and body fat components due to improper dietary energy capture, Often due to aging, deeply related to age. Therefore, there is a need for research to prevent muscle loss or muscle loss due to aging.

  Muscle strengthening effects have been reported since the end of the 90s through a mechanism in which branched-chain amino acids containing leucine synthesize proteins in muscle cells through mTOR (Mammalian Target of Rapamycin) signaling. The research direction has been carried out in two major parts. The first is research on whether a specific amino acid has a muscle strengthening effect through mTOR. On the other hand, as a result of measuring the muscle strengthening effect with individual amino acids removed, branched-chain amino acids are effective. Among them, leucine was reported to be most effective. Moreover, in the synergy effect between many amino acids, it has been reported that glutamine promotes intracellular absorption of leucine and increases the muscle strengthening effect through mTOR signal transmission. The second is a study on how amino acids are recognized in cells to activate mTOR signaling. In contrast, Vps34, MAP4K3, and Rag GTPase have been reported since the late 2000s. It has been presented to intermediate mediators. Thereafter, the present inventor has revealed that mTOR is activated when leucine-tRNA synthase directly recognizes leucine and activates Rag GTPase.

  However, all the mTOR signal transmission mechanisms only increase muscle synthesis by increasing the synthesis of protein in muscle, and differentiate myoblasts into muscle cells to increase the number of muscle cells themselves. This is different from the mechanism that fundamentally recovers the lost or lost muscle mass.

  Here, as a result of diligent efforts to find a method for increasing the differentiation formation of muscle cells, which is not the synthesis of intramuscular proteins, the present inventors found that phenylalanine and methionine are among amino acids. It was confirmed that the loss of senile muscle can be prevented, improved or treated by acting together to promote the differentiation of myoblasts into muscle cells, and the present invention has been completed.

  An object of the present invention is to provide a composition for promoting myocyte differentiation, further comprising a myocyte differentiation promoting agent comprising phenylalanine (Phe) and methionine (Met), and a pharmaceutically or food acceptable additive. Is to provide.

  That is, an object of the present invention is to provide a pharmaceutical composition for preventing or treating senile muscle loss or a health functional food composition for preventing or improving, which contains the above-described muscle cell differentiation promoter as an active ingredient.

  In order to achieve the above object, the present invention provides a myocyte differentiation promoter comprising phenylalanine (Phe) and methionine (Met).

  The present invention also provides a composition for promoting myocyte differentiation, which contains the myocyte differentiation promoting agent according to the present invention as a main component and further contains a pharmaceutically or food-acceptable additive as an auxiliary component. To do.

  The present invention also provides a pharmaceutical composition for preventing or treating senile muscle loss, comprising the composition for promoting myocyte differentiation according to the present invention.

  The present invention also provides a health functional food composition for preventing or improving senile muscle loss, comprising the composition for promoting myocyte differentiation according to the present invention.

  The composition for promoting the differentiation of muscle cells of the present invention and the pharmaceutical composition or health functional food composition containing the same promote the differentiation of myoblasts into muscle cells to prevent sarcopenia and muscle loss. It can be improved and treated, and is particularly effective for senile muscle loss. The increase in the number of muscle cells increases the basal metabolic rate and oxidizes body fatty acids.

It is the figure which observed the cell pattern change by the differentiation of a C2C12 cell in the amino acid deficiency condition with the microscope.

It is the figure which observed the cell pattern change by the differentiation of L6 cell with the microscope in the amino acid deficiency condition.

It is the figure which analyzed the expression pattern of the differentiation marker protein (MyoD and Myogenin) of C2C12 cell in the deficient condition of various essential amino acids through a Western blot.

It is the figure which experimented and observed whether it influences the differentiation of C2C12 cell concentration-dependently, when a tylosin (Tyr) or phenylalanine is processed to a C2C12 cell in the amino acid deficiency situation among amino acids.

It is the figure which experimented and observed whether or not when Tylosine or phenylalanine was processed to L6 cells in the amino acid deficiency situation among amino acids, it influenced the differentiation of L6 cells in a concentration-dependent manner.

It is the figure which analyzed whether the expression of a myocyte marker gene was influenced depending on a density | concentration when processing a tylosin or phenylalanine to a C2C12 cell in the deficiency of phenylalanine among amino acids.

It is the figure which analyzed whether it influences concentration-dependently on the expression of a myocyte marker gene, when a tylosin or phenylalanine is processed to a L6 cell in the condition of a deficiency of phenylalanine among amino acids.

It is the figure which observed by experimenting whether or not it influences the differentiation of C2C12 cells in a concentration-dependent manner when tylosin or phenylalanine is treated to C2C12 cells in a situation where the whole amino acid is deficient.

It is the figure which observed by experimenting whether it influences the differentiation of a L6 cell in a density | concentration dependence, when a tylosin or phenylalanine is processed to a L6 cell in the deficiency state of the whole amino acid.

It is the figure which analyzed whether it influences concentration-dependently on the expression of a myocyte marker gene, when a tylosin or a phenylalanine is processed to a C2C12 cell in the deficiency state of the whole amino acid.

It is the figure which analyzed whether it influences concentration-dependently on the expression of a myocyte marker gene, when a tylosin or phenylalanine is processed to L6 cell in the deficiency state of the whole amino acid.

It is the figure observed experimentally whether it influences on differentiation of C2C12 cell concentration-dependently, when processing methionine to C2C12 cell in the deficiency state of the whole amino acid.

It is the figure which observed by experimenting whether or not it influences the differentiation of L6 cells in a concentration-dependent manner when methionine is processed into L6 cells in a state where the whole amino acid is deficient.

It is the figure which analyzed whether it affected concentration of the expression of a myocyte marker gene when processing methionine to C2C12 cell in the deficiency state of the whole amino acid.

It is the figure which analyzed whether it influences the expression of a myocyte marker gene in a density | concentration when processing methionine to L6 cell in the deficiency state of the whole amino acid.

When phenylalanine, methionine, or various ratios of phenylalanine + methionine are treated into C2C12 cells in a state where the whole amino acid is deficient, changes in the expression pattern of the myocyte marker gene are observed.

When L6 cells are treated with phenylalanine, methionine or various ratios of phenylalanine + methionine in a state where all amino acids are deficient, changes in the expression pattern of myocyte marker genes are observed.

  Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In general, the nomenclature used herein is commonly used in the art.

  As used herein, “myoblast” means a stem cell having the ability to differentiate into muscle cells. These myoblasts may be specifically reverse differentiated into satellite cells, but this phenomenon occurs in some myoblasts that do not undergo long-term conversion to muscle cells. However, such satellite cells can differentiate from myoblasts to muscle cells at any time when given an appropriate stimulus (such as exercise).

  “Myoblast differentiation” used in the present invention is a process in which mononuclear myoblasts form multinucleated myotubes through fusion. In the process of differentiation from myoblasts to myotubes, the expression of genes such as myosin D (MyoD) and myogenin increases. Therefore, if myosin D and myogenin are used as myoblast differentiation marker genes, the presence or absence of myocyte differentiation can be confirmed.

  The term “muscle cell differentiation / formation” used in the present invention means that myoblasts are differentiated to form muscle cells having characteristics of muscle such as myofiber and containing many mitochondria together with a change to a long pattern. This means that the formed muscle cells form a multinucleated myotube through fusion. However, myotube formation through cell fusion is a phenomenon that occurs only in skeletal muscle and not in myocardium and smooth muscle.

  The stem cell “differentiation” used in the present invention includes not only a case where a stem cell is completely differentiated into a specific cell, but also an intermediate stage before the stem cell is completely differentiated into a specific cell.

  Hereinafter, the present invention will be specifically described.

  In the present invention, in order to confirm which amino acid among 9 types of amino acids (Leu, Ile, Met, Val, Lys, Trp, Phe, Thr, Gln) including phenylalanine and methionine affects the differentiation formation of muscle cells. The experiment was conducted. As a result, especially when phenylalanine (Phe) and methionine (Met) are deficient, it is found that differentiation formation of muscle cells is greatly inhibited. When the mixing ratio of phenylalanine and methionine is 2: 1 by weight, It was confirmed that the most differentiated formation of cells occurred.

  Therefore, this invention relates to the myocyte differentiation promoter which consists of phenylalanine (Phe) and methionine (Met) from one viewpoint.

  In the present invention, the myelin differentiation promoting agent phenylalanine (Phe) and methionine (Met) may be mixed in a weight ratio of 1: 4 to 4: 1, preferably 2: 1. When included in the weight ratio, it is not only suitable for exhibiting the differentiation formation effect of muscle cells, but also can satisfy all of the stability and safety of the composition. It is appropriate to include in the range.

  The phenylalanine and / or methionine may be present as a monomer, oligomer, polymer, or the like.

  Another aspect of the present invention is a composition for promoting myocyte differentiation, which contains the myocyte differentiation promoter according to the present invention as a main component and further contains a pharmaceutically or food-acceptable additive as an auxiliary component. Related to things.

  In the present invention, the composition for promoting myocyte differentiation is any one selected from the group consisting of threonine (Thr), valine (Val), isoleucine (Ile), glutamine (Gln), and lysine (Lys). It may be characterized by further containing the above amino acids as auxiliary components.

  The phenylalanine (Phe) is contained in an amount of 0.02 to 64% by weight, preferably 0.05 to 54% by weight, based on the total weight of the composition, and methionine (Met) is preferably 0.02 to 64% by weight, preferably. May be contained at 0.05 to 27% by weight. If the sum of the two amino acid contents is less than 0.1% by weight, the effect is weak. If it exceeds 80% by weight, the patient having a problem with amino acid metabolism is hyperphenylalaninemia (excluding phenylketonuria). And hypermethionineemia (outside hyperhomocysteinemia) may occur. Therefore, although there is no problem in the case of normal persons, it is preferable to use the amount of the phenylalanine / methionine mixed preparation between 0.1 to 80% by weight with respect to the total weight of the composition in consideration of patients with abnormal amino acid metabolism. .

  In another aspect, the present invention relates to a pharmaceutical composition for preventing or treating senile muscle loss, which contains the myocyte differentiation promoter according to the present invention as an active ingredient.

  When the composition according to the present invention is applied to a pharmaceutical composition, it can be formulated into a solid, semi-solid or liquid form by adding an inorganic or organic carrier commonly used as an active ingredient. If the active ingredient of the present invention is carried out by a conventional method, it can be easily formulated into a surfactant, excipient, coloring agent, spice, stabilizer, preservative, preservative, wettable powder, emulsification promotion. Agents, suspensions, salts and / or buffers for adjusting osmotic pressure, and other commonly used adjuvants can be appropriately used.

  Examples of the preparation for oral administration include tablets, pills, granules, soft and hard capsules, powders, fine granules, powders, solutions, suspensions, emulsions, syrups, pellets, etc. Can do. In addition to the active ingredients, these dosage forms include diluents (eg, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and glycine), lubricants (eg, silica, talc, stearic acid and its magnesium or calcium salts and polyethylene glycol) Can be contained. Tablets can also contain binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose or polyvinylpyrrolidone, and in some cases, such as starch, agar, alginic acid or its sodium salt Pharmaceutical additives such as disintegrants, absorbents, colorants, flavoring agents or sweetening agents can be included. The tablets can be manufactured by conventional mixing, granulating or coating methods.

  The pharmaceutical composition according to the present invention can be administered orally, parenterally, rectally, topically, transdermally, intravenously, intramuscularly, intraperitoneally, subcutaneously and the like.

  The dosage of the active ingredient may vary depending on the age, sex, weight or specific disease or pathological condition to be treated, the severity of the disease or pathological condition, the route of administration or the judgment of the prescriber. Determination of dosage based on such factors is within the level of ordinary skill in the art. Typical dosages may preferably be between 1.375 mg / kg / day to 1100 mg / kg / day, but the dosages do not limit the scope of the invention in any way.

  In another aspect, the present invention also relates to a health functional food composition for preventing or ameliorating senile muscle loss, comprising the myocyte differentiation promoter according to the present invention as an active ingredient.

  The dosage form of the health functional food composition is not particularly limited, and can be formulated into tablets, granules, drinks, caramel, diet bars, drinks, and the like. In addition to the active ingredients, each dosage form of the food composition can be appropriately selected and formulated by the person skilled in the art without difficulty according to the dosage form or purpose of use, and can be combined with other ingredients. If you do, you can have a rising effect.

  The determination of the dosage of the active ingredient is within the level of ordinary skill in the art, and this daily dosage may vary depending on various factors such as the age, health status, and complications of the subject to be administered.

  Hereinafter, the present invention will be described in more detail through examples. These examples are merely to illustrate the present invention, and it is obvious to those skilled in the art that the scope of the present invention is not construed to be limited by these examples. Accordingly, the substantial scope of the present invention may be defined by the appended claims and their equivalents.

[Test Example 1] Confirmation of muscle cell differentiation formation effect due to essential amino acid deficiency C2C12 muscles in any one of 9 amino acids (Leu, Ile, Met, Val, Lys, Trp, Phe, Thr, Gln) As a result of observing the cell differentiation formation process using Olympus CK40 optical microscope (40x), as shown in FIG. 1, among the nine amino acids, phenylalanine (Phe) deficiency is the differentiation formation of muscle cells. It was found that methionine (Met) deficiency inhibited muscle cell differentiation after phenylalanine. Therefore, it was confirmed that sufficient provision of phenylalanine and methionine is important for the formation of muscle cells.

  As a result of observing the differentiation formation process in L6 cells, which are other types of muscle cells, in the same manner as described above, as shown in FIG. 2, the effect of phenylalanine deficiency on the differentiation formation of muscle cells is the largest as in C2C12. Also, methionine deficiency was found to have a significant effect.

  Based on the results of the two experiments, the effects of nine amino acids on the formation of muscle cell differentiation could be arranged according to the following procedure.

  Total essential amino acids> Phe> Met> Thr = Val = Ile = Gln = Lys> Leu = Trp

  The total amino acid deficiency had the greatest effect on muscle cell differentiation (slowest differentiation), followed by phenylalanine deficiency, followed by methionine deficiency. It was confirmed that tryptophan deficiency had the least effect on muscle cell differentiation.

  In addition to observing cell pattern changes during differentiation of muscle cells, and extracting proteins from differentiated muscle cells to investigate the expression pattern of differentiation marker proteins (myosin D and myogenin), myosin D and myogenin-specific antibodies Comparative analysis was performed using Western blotting methods commonly used in the art. As shown in FIG. 3, it can be confirmed that the expression of the differentiation marker protein is remarkably reduced in the situation where phenylalanine is deficient, as in the observation result by the optical microscope. It was confirmed that methionine deficiency also decreased the expression of differentiation marker protein.

Test Example 2 Confirmation of Muscle Cell Differentiation Formation Effect of Phenylalanine According to Test Example 1, the most significant effect of phenylalanine on the formation of muscle cell differentiation appears among the essential amino acids, and the addition of phenylalanine promotes the formation of muscle cell differentiation. Subsequent experiments were set up to see what could be done. In addition, considering the fact that phenylalanine is converted to tylosin (Tyr) in the amino acid metabolic pathway, an experiment was conducted together to examine whether tylosin deficiency affects muscle cell formation. After adding tylosin or phenylalanine at different concentrations (0.2 mM, 0.4 mM, 0.8 mM) to the cell culture medium lacking phenylalanine, the differentiation forming ability of each of C2C12 cells and L6 cells was the same as in Test Example 1. And measured using an optical microscope.

  As a result, as shown in FIG. 4 (C2C12) and FIG. 5 (L6), it was found that phenylalanine, rather than tylosin, affects muscle cell formation in a concentration-dependent manner.

  In each case, in order to confirm the expression of the muscle cell marker gene, RNA is extracted from the differentiated muscle cells as in the qRT-PCR method usually used in the art, and complementary based on this. After synthesizing DNA (cDNA), the mRNA expression change of the marker gene was observed by using PCR primer of myosin D and myogenin in qRT-PCR (quantitative real-time polymerase chain reaction).

  As a result, as shown in FIG. 6 (C2C12) and FIG. 7 (L6), it was confirmed that the mRNA expression level of the differentiation marker gene Myo D also appeared in a concentration-dependent manner.

  In addition, in order to confirm the effects of phenylalanine and tylosin on muscle cell formation, after adding phenylalanine or tylosin for each concentration (0.2 mM, 0.4 mM, 0.8 mM) to the cell culture medium completely depleted of amino acids. The ability of C2C12 cells and L6 muscle cells to form differentiation was measured by the same method as described above.

  As a result, as shown in FIG. 8 (C2C12) and FIG. 9 (L6), when phenylalanine, which is not tylosin, was added, the result that muscle forming ability was increased could be confirmed once more. Moreover, as shown in FIG. 10 (C2C12) and FIG. 11 (L6), it was confirmed that the expression of each muscle cell marker gene was increased only by the addition of phenylalanine.

[Test Example 3] Confirmation of muscle cell differentiation formation effect of methionine Through the results of Test Example 1, methionine is not as much as phenylalanine, but it is analogized that it has a greater effect on muscle cell differentiation than other essential amino acids. We were able to. In this connection, in order to examine whether differentiation of muscle cells is possible by addition of methionine, after addition of methionine to C2C12 and L6 cells lacking amino acids, the presence or absence of differentiation into muscle cells was determined. Observed.

  As a result, as shown in FIG. 12 (C2C12) and FIG. 13 (L6), it can be confirmed that methionine alone affects muscle cell differentiation, and FIG. 14 (C2C12) and FIG. 15 (L6) As shown, it was once again confirmed that methionine affects the formation of muscle cells by increasing the expression of muscle cell marker genes.

[Example] Confirmation of muscle cell formation effect by mixing ratio of phenylalanine and methionine Focusing on the point that phenylalanine and methionine were most effective for the differentiation of muscle cells among the amino acids in Test Examples 1 to 3, the optimal effect Examples 1 to 7 were prepared with the components and contents shown in Table 1 below to determine the mixing ratio of phenylalanine and methionine. Comparative Example 1 was prepared without any methionine, and Comparative Example 2 was prepared with no phenylalanine. In addition, a small amount of branched chain amino acids (leucine, valine, isoleucine), which are known to induce muscle protein synthesis, have a slight effect on muscle cell differentiation.

  Examples 1 to 7 and Comparative Examples 1 and 2 were processed into C2C12 cells and L6 cells in the same manner as described in Test Examples 1 to 3, and the differentiation formation of muscle cells was observed and measured. As a result, as shown in FIG. 16 (C2C12) and FIG. 17 (L6), it is confirmed that the muscle cell differentiation forming effect of Example 3 in which phenylalanine and methionine are mixed at a weight ratio of 2: 1 is most excellent. did it.

  Although specific portions of the contents of the present invention have been described in detail above, such specific techniques are merely preferred embodiments for those having ordinary knowledge in the technical field, and the scope of the present invention is thereby limited. It will be clear that it is not limited. Accordingly, the substantial scope of the present invention is defined by the appended claims and their equivalents.

  Moreover, although the pharmaceutical composition containing the composition of this invention and the dosage-form example of a health functional food composition are demonstrated in more detail below, it is clear that the scope of the present invention is not restrict | limited by this.

[Dosage Form Example 1] Tablet Production Example 3 . . . . . . . . . . . . 50mg
Corn starch. . . . . . . . . . 100mg
lactose. . . . . . . . . . . . . . . . 100mg
Magnesium stearate. . . . . . . . 2mg
Vitamin C. . . . . . . . . . . . . . . 50mg

  After mixing the above ingredients, tablets are produced by tableting by a conventional tablet production method.

[Dosage Form Example 2] Capsule Production Example 3 . . . . . . . . . . . . . . 50mg
Corn starch. . . . . . . . . . 100mg
lactose. . . . . . . . . . . . . . . . 100mg
Magnesium stearate. . . . . . . 2mg
Vitamin C. . . . . . . . . . . . . . 50mg
Serine. . . . . . . . . . . . . . . . 50mg

  The above ingredients are mixed and filled into gelatin capsules by a conventional capsule production method to produce capsules.

[Dosage Form Example 3] Production Example 3 of Liquid Solution . . . . . . . . . . . . . 100mg
Isomerized sugar. . . . . . . . . . . . . . . . 10g
Mannitol. . . . . . . . . . . . . . . . 5g
Vitamin C. . . . . . . . . . . . . . . 50mg
Serine. . . . . . . . . . . . . . . . . 50mg
Oils and fats. . . . . . . . . . . . . . . . . . . . Appropriate amount of purified water. . . . . . . . . . . . . . . . . . . Remaining amount

  Add each ingredient to purified water and dissolve it with the usual solution manufacturing method, add lemon fragrance in an appropriate amount, mix the ingredients, then add purified water to adjust the total volume to 100 ml, then fill into a light-shielding bottle. And sterilize to produce a solution.

[Formulation Example 4] Production Example of Health Functional Food Example 3. . . . . . . . . . . . . . 1000mg
Vitamin mixture vitamin A acetate. . . . . . . . . 70 μg
Vitamin E. . . . . . . . . . . . . . 1.0mg
Vitamin B1. . . . . . . . . . . . . 0.13mg
Vitamin B2. . . . . . . . . . . . 0.15mg
Vitamin B6. . . . . . . . . . . . . . 0.5mg
Vitamin B12. . . . . . . . . . . . . 0.2 μg
Vitamin C. . . . . . . . . . . . . . . 10mg
Biotin. . . . . . . . . . . . . . . . . 10 μg
Nicotinamide. . . . . . . . . . . . 1.7mg
Folic acid. . . . . . . . . . . . . . . . . . . . 50 μg
Calcium pantothenate. . . . . . . . . . 0.5mg
Inorganic mixture ferrous sulfate. . . . . . . . . . . . . . . 1.75mg
Zinc oxide. . . . . . . . . . . . . . . . 0.82mg
Magnesium carbonate. . . . . . . . . . . . 25.3mg
Primary calcium phosphate. . . . . . . . . . . . 15mg
Dicalcium phosphate. . . . . . . . . . . . 55mg
Potassium citrate. . . . . . . . . . . . . . 90mg
Calcium carbonate. . . . . . . . . . . . . . 100mg
Magnesium chloride. . . . . . . . . . . . . 24.8mg

  The composition ratio of the vitamin and mineral mixture was mixed with components suitable for health foods in a preferred embodiment, but the blending ratio may be arbitrarily changed, and the ingredients may be changed by a normal health food manufacturing method. After mixing, a granule is manufactured and can be used for manufacturing a health functional food composition by an ordinary method.

[Form 5] Drink production example 3. . . . . . . . . . . . . . 1000mg
citric acid. . . . . . . . . . . . . . 1000mg
oligosaccharide. . . . . . . . . . . . . . . . 100g
Plum concentrate. . . . . . . . . . . . . . . . . . 2g
Taurine. . . . . . . . . . . . . . . . . . 1g
Add purified water to the whole. . . . . . . . . . . 1000ml

The above ingredients are mixed by a usual method for producing a drink, and then stirred and heated at 85 ° C. for about 1 hour. The prepared solution is filtered to obtain a sterilized 2 L container, and then sterilized in a sealed manner, and then refrigerated for use in producing the drink composition of the present invention.

Claims (8)

  A myocyte differentiation promoter comprising phenylalanine (Phe) and methionine (Met).   The muscle cell differentiation promoter according to claim 1, wherein the phenylalanine (Phe) and methionine (Met) are mixed in a weight ratio of 1: 4 to 4: 1.   A composition for promoting myocyte differentiation, comprising the myocyte differentiation promoting agent of claim 1 as a main component and further containing a pharmaceutically or food-acceptable additive as an auxiliary component.   It further comprises any one or more amino acids selected from the group consisting of threonine (Thr), valine (Val), isoleucine (Ile), glutamine (Gln) and lysine (Lys) as an auxiliary component. The composition for promoting myocyte differentiation according to claim 3.   A pharmaceutical composition for preventing or treating senile muscle loss, comprising the muscle cell differentiation promoter of claim 1 or 2 as an active ingredient.   A health functional food composition for preventing or improving senile muscle loss, comprising the muscle cell differentiation promoter of claim 1 or 2 as an active ingredient.   Use of phenylalanine and methionine as myocyte differentiation promoters in the manufacture of pharmaceutical compositions. Use of phenylalanine and methionine as myocyte differentiation promoters in the production of health functional food compositions.

Images